Last updated: 19 June 2019 at 3:29am EST

Stephen B Brugger Net Worth




The estimated Net Worth of Stephen B Brugger is at least $16.2 Million dollars as of 28 October 2010. Stephen Brugger owns over 55,730 units of Momenta Pharmaceuticals stock worth over $13,902,897 and over the last 20 years Stephen sold MNTA stock worth over $2,315,373.

Stephen Brugger MNTA stock SEC Form 4 insiders trading

Stephen has made over 15 trades of the Momenta Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Stephen exercised 55,730 units of MNTA stock worth $12,818 on 28 October 2010.

The largest trade Stephen's ever made was exercising 82,510 units of Momenta Pharmaceuticals stock on 6 September 2005 worth over $18,977. On average, Stephen trades about 11,683 units every 85 days since 2005. As of 28 October 2010 Stephen still owns at least 264,918 units of Momenta Pharmaceuticals stock.

You can see the complete history of Stephen Brugger stock trades at the bottom of the page.



What's Stephen Brugger's mailing address?

Stephen's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler, and Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.



What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.



Complete history of Stephen Brugger stock trades at Momenta Pharmaceuticals

Insider
Trans.
Transaction
Total value
Stephen B Brugger
Vice President and Strategic Prod Devl.
Option $12,818
28 Oct 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $7,572
26 Aug 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $2,039
24 Aug 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $926,756
3 Aug 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $5,690
26 May 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $1,572
25 May 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $118,014
10 Mar 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $488,474
8 Mar 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $20,700
1 Mar 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $1,539
23 Feb 2010
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $2,087
24 Aug 2009
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $852
22 May 2009
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $5,512
23 Feb 2009
Stephen B Brugger
Vice President and Strategic Prod Devl.
Sale $734,565
17 Feb 2006
Stephen B Brugger
Vice President and Strategic Prod Devl.
Option $18,977
6 Sep 2005


Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: